Vitestro's revolutionary autonomous blood drawing device receives CE marking, transforming the way blood samples are collected and addressing healthcare staffing challenges.
 |
| Vitestro's groundbreaking device is the first of its kind to receive CE marking, marking a significant milestone in the automation of blood sample collection. Image: Vitestro |
Utrecht, Netherlands - August 28, 2024:
Vitestro, a leader in medical robotics, has achieved a significant milestone with the CE marking of its innovative autonomous blood drawing device. This certification validates the device's safety, efficacy, and quality, paving the way for its commercialization across the European Union.
The CE marking is a testament to Vitestro's groundbreaking technology, which has the potential to revolutionize the process of blood sample collection. By combining advanced imaging technology and robotics, the device offers autonomous blood draws, reducing the need for manual handling and improving patient and clinician satisfaction. This automation is particularly crucial as clinical laboratories grapple with a severe staffing shortage.
Co-founder and CEO Toon Overbeeke expressed his excitement about this achievement, stating that it not only marks a major milestone for Vitestro but also signifies a transformative moment for healthcare. "This innovation introduces a completely novel type of medical device—one that allows European hospitals to use autonomous technology to perform invasive medical procedures independently," he said. "We believe this technology is foundational, setting a new global standard that will benefit patients and help hospitals prepare for a challenging future."
Several leading European hospitals and clinical laboratories have already placed orders for the device. With the CE marking secured, Vitestro plans a limited market release at selected hospitals within the next 12 months. Production will subsequently be scaled up, adhering to the company's proven Quality Assurance processes.
Maxine Moor, VP of Commercial Europe, emphasized the significant need for phlebotomy automation within the European clinical laboratory market. "Vitestro has been engaging with clinical labs across Europe for several years, and they have consistently expressed a strong desire for this innovation," she said. "We are excited to begin implementing our devices in hospitals and laboratories in the coming 12 months. While we will start within the Netherlands and Denmark, we have broader international ambitions. With the CE mark, we are also meeting regulatory demands for the UK market."
Vitestro's achievement marks a significant step forward in the field of medical robotics. As the company expands its market presence, it is poised to make a substantial impact on healthcare by improving efficiency, reducing human error, and enhancing patient care.